Skip to main content
PharmaTher Holdings Ltd. logo

PharmaTher Holdings Ltd. — Investor Relations & Filings

Ticker · PHRM ISIN · CA71716H1082 LEI · 529900PIPSZ1ZSWF3A21 CSE Manufacturing
Open in API
Filings indexed 279 across all filing types
Latest filing 2025-04-25 Regulatory Filings
Country CA Canada
Listing CSE PHRM

About PharmaTher Holdings Ltd.

https://www.pharmather.com/

PharmaTher Holdings Ltd. is a specialty pharmaceutical company dedicated to the research, development, and commercialization of novel therapeutics, primarily focusing on ketamine and psychedelic compounds. The company's strategy involves advancing three core assets: the KETARX™ portfolio of ketamine drugs, which targets neuropsychiatric and pain disorders; the proprietary PharmaPatch™ microneedle patch platform, designed for the transdermal delivery of ketamine, psychedelics, and GLP-1 drugs; and a 49% ownership interest in Sairiyo Therapeutics Inc., which is developing a patented oral formulation of cepharanthine for infectious diseases and cancer. PharmaTher is focused on achieving regulatory approval for its pipeline candidates to address significant global unmet medical needs in mental health, neurological, and pain disorders.

Recent filings

Filing Released Lang Actions
Interim financial statements/report – English.pdf
Regulatory Filings
2025-04-25 English
News release - English.pdf
Regulatory Filings Classification · 80% confidence The document is a corporate press release announcing the FDA’s assignment of a new approval goal date for PharmaTher’s ketamine New Drug Application. It is a regulatory update rather than a financial report, earnings release, or other specific filing. It does not present financial results, proxy materials, management changes, or dividend details. Therefore, it falls under a general regulatory announcement/fallback category.
2025-03-11 English
News release - English.pdf
Regulatory Filings Classification · 75% confidence The document is a corporate press release announcing the company’s resubmission of a Complete Response Amendment to the FDA for its new drug application for Ketamine. It does not present financial results (so it’s not an Earnings Release/ER), nor is it a report itself (e.g., 10-K, IR), nor an AGM/EGM material. It is a general regulatory update/announcement that does not fit into any highly specific category, so it falls into the fallback category “Regulatory Filings (RNS).”
2025-03-03 English
News release - English.pdf
Regulatory Filings Classification · 85% confidence The document is a corporate press release providing an operational update on the company’s regulatory submission to the FDA. It is not a formal financial report, earnings release, or change in corporate governance or capital structure. It does not present financial results, board changes, or dividend information. It is a general regulatory announcement about the status of a New Drug Application process. Therefore it falls into the fallback “Regulatory Filings” category (RNS).
2025-02-12 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Investor Presentation Classification · 90% confidence The document is a '2025 Shareholder Letter' from Jewett-Cameron Trading Company. It provides a narrative overview of the company's strategic initiatives, operational updates, and future outlook. It does not contain formal financial statements, audit reports, or regulatory filings, but rather serves as a communication piece from the CEO to shareholders. In the context of corporate filings, such letters are typically categorized as part of the company's investor relations materials or annual reporting package. Given the specific categories provided, this document fits best as an Investor Presentation (IP) or a general corporate communication, but since it is a standalone narrative letter, it is most accurately classified as an Investor Presentation (IP) as it outlines strategy, market position, and growth initiatives. FY 2025
2025-01-27 English
Interim MD&A - English.pdf
Management Reports Classification · 95% confidence The document is titled “Interim Management’s Discussion and Analysis – Quarterly Highlights” for the three and six months ended November 30, 2024, and contains management’s discussion of business operations, liquidity, capital resources, forward-looking statements, risk factors, and an overview of the company’s interim results. It is not a full interim financial report (with financial statements) but rather the MD&A section. This matches the definition of a Management Reports (MDA) filing.
2025-01-27 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.